<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR91" class="ref">
 <label class="label">91.</label>
 <element-citation publication-type="journal" class="element-citation">
  <person-group person-group-type="author" class="person-group">
   <name class="name">
    <surname class="surname">Narhi</surname>
    <given-names class="given-names">LO</given-names>
   </name>
   <name class="name">
    <surname class="surname">Corvari</surname>
    <given-names class="given-names">V</given-names>
   </name>
   <name class="name">
    <surname class="surname">Ripple</surname>
    <given-names class="given-names">DC</given-names>
   </name>
   <name class="name">
    <surname class="surname">Afonina</surname>
    <given-names class="given-names">N</given-names>
   </name>
   <name class="name">
    <surname class="surname">Cecchini</surname>
    <given-names class="given-names">I</given-names>
   </name>
   <name class="name">
    <surname class="surname">Defelippis</surname>
    <given-names class="given-names">MR</given-names>
   </name>
   <etal class="etal"/>
  </person-group>
  <article-title class="article-title">Subvisible (2-100 mum) particle analysis during biotherapeutic drug product development: part 1, considerations and strategy</article-title>
  <source class="source">J Pharm Sci</source>
  <year class="year">2015</year>
  <volume class="volume">104</volume>
  <issue class="issue">6</issue>
  <fpage class="fpage">1899</fpage>
  <lpage class="lpage">1908</lpage>
  <?supplied-pmid 25832583?>
  <pub-id pub-id-type="pmid" class="pub-id">25832583</pub-id>
 </element-citation>
</ref>
